Core Viewpoint - Avoro Capital Advisors LLC significantly reduced its stake in BioCryst Pharmaceuticals by 72.2% in Q3, indicating a shift in investment strategy towards the biotechnology company [2] Institutional Holdings - Avoro Capital Advisors LLC now holds 1,250,000 shares of BioCryst Pharmaceuticals, down from 3,250,000 shares, making it the 28th largest holding in their portfolio [2] - Arrowstreet Capital increased its position by 2,103.7% in Q2, now owning 4,278,555 shares valued at $38,336,000 after purchasing an additional 4,084,403 shares [3] - Qube Research & Technologies raised its stake by 152.3% in Q2, now holding 2,373,489 shares worth $21,266,000 [3] - Bank of America Corp DE grew its stake by 97.9% in Q2, owning 2,841,155 shares valued at $25,457,000 [3] - BNP Paribas Financial Markets lifted its position by 1,059.7% in Q2, now owning 1,456,857 shares valued at $13,053,000 [3] - Vanguard Group Inc. increased its position by 6.1% in Q3, now holding 21,790,881 shares valued at $165,393,000 [3] - Institutional investors collectively own 85.88% of BioCryst Pharmaceuticals [3] Stock Performance - BioCryst Pharmaceuticals stock opened at $8.22, with a 52-week low of $6.00 and a high of $11.31 [4] - The company has a market capitalization of $2.06 billion, a P/E ratio of 6.85, and a beta of 0.74 [4] - The stock's 50-day moving average price is $7.31, and the 200-day moving average price is $7.41 [4] Financial Performance - BioCryst Pharmaceuticals reported $1.12 earnings per share (EPS) for the last quarter, exceeding analysts' expectations of $0.07 by $1.05 [5] - The company had a net margin of 30.16% and a negative return on equity of 84.33% [5] - Revenue for the quarter was $163.28 million, up 209.1% compared to the same quarter last year, surpassing expectations of $151.32 million [5] Insider Activity - Insider Alane P. Barnes sold 21,773 shares at an average price of $7.65, totaling approximately $166,563.45, resulting in a 5.18% decrease in ownership [6] Analyst Ratings - Evercore issued an "outperform" rating with a target price of $17.00 [7] - Weiss Ratings upgraded the stock from "sell (d-)" to "hold (c)" [7] - HC Wainwright raised its price objective from $30.00 to $32.00, maintaining a "buy" rating [7] - Royal Bank Of Canada reduced its price objective from $14.00 to $13.00 while keeping an "outperform" rating [7] - The consensus rating for BioCryst Pharmaceuticals is "Moderate Buy" with a target price of $19.64 [7] Company Overview - BioCryst Pharmaceuticals is a clinical-stage biotechnology company focused on developing novel oral small-molecule medicines for rare and serious diseases [8] - The company's first commercial product, Orladeyo (berotralstat), is approved for the prophylactic treatment of hereditary angioedema in the U.S. and Europe [9]

Core Insights - A Co-CEO of Amylyx Pharmaceuticals executed significant insider selling, but the sale was primarily to cover option costs and tax obligations, not discretionary [6][7] - The company has shown strong stock performance, with a 313% increase over the past year, recovering from previous losses [4][7] Transaction Summary - Joshua B Cohen sold 138,167 shares for approximately $1.9 million, following the exercise of 200,000 stock options [1][2] - Post-transaction, Cohen holds 3,379,465 shares, representing a 4.07% insider ownership [2][7] Company Overview - Amylyx Pharmaceuticals focuses on developing therapeutics for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS) [5] - The company is advancing its flagship therapy, AMX0035 (RELYVRIO), which has shown effectiveness in slowing ALS progression [8] Financial Performance - The company's market capitalization is $1.57 billion, with a net income of -$149.28 million [4] - The stock price as of January 31, 2026, was $14.29, reflecting a significant recovery and growth [4] Investigations - Amylyx is currently under investigation for alleged breaches of fiduciary duties by its directors and officers, which may be a concern for investors [9]